MoonLake Immunotherapeutics
MLTXNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $912.11M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $8.90$23.29
- Volume (live)
- -
- Avg. volume (3M)
- 2.02M
MoonLake Immunotherapeutics (MLTX) Stock Price & Financial Analysis
MoonLake Immunotherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.65 - $13.33 |
|---|---|
| 52-Week High | $23.29 |
| 52-Week Low | $8.90 |
| Open | $10.70 |
| Volume (last close) | 6.12M |
| Average Volume (3M) | 2.02M |
| 50-Day MA | $13.26 |
|---|---|
| 200-Day MA | $16.58 |
| 1-Year Change | +30.44% |
| Market Cap | 912.11M |
|---|---|
| Shares Outstanding | 73.92M |
| Price to Book (P/B) | 2.13 |
| EV/EBITDA | -2.14 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
MoonLake Immunotherapeutics at a Glance
As of the Oct 22, 2026 close, MoonLake Immunotherapeutics (MLTX) has a market capitalization of $912.11M.
As of its latest reported balance sheet, it holds $477.90M in cash and securities against $101.53M of debt, a net cash position of $376.37M.
MoonLake Immunotherapeutics does not currently pay a dividend.
The share price is up 30.4% over the past year. At $12.34 (the Oct 22, 2026 close) it sits within its 52-week range of $8.90 to $23.29, below its 200-day moving average of $16.58.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $33.00, 167.4% above the Oct 22, 2026 close.
Frequently Asked Questions About MoonLake Immunotherapeutics
What is the current stock price for MLTX?
As of the Oct 22, 2026 close, MLTX stock trades at $12.34. The 52-week range is $8.90–$23.29, with a day range of $10.65–$13.33.
What is the P/E ratio for MLTX?
The P/E ratio (Price-to-Earnings) for MLTX is shown in the Key Statistics section. This valuation metric helps compare MoonLake Immunotherapeutics to industry peers.
Does MLTX pay dividends?
MoonLake Immunotherapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for MLTX?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for MLTX is Buy. The average 12-month price target is $33.00, a 167.4% upside from the Oct 22, 2026 close of $12.34.
What is the market cap of MLTX?
As of the Oct 22, 2026 close, MoonLake Immunotherapeutics's market capitalization is $912.1M, classifying it as a small-cap company. MoonLake Immunotherapeutics operates in the Healthcare sector within the Biotechnology industry.